1-4 of 4
Christine Jarjies, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Alison J. Moskowitz, MD, Gunjan Shah, MD, Heiko Schöder, MD, Nivetha Ganesan, MPH, Helen Hancock, ANP, Theresa Davey, MMSc, PA-C, Samia Sohail, BA, Alayna Santarosa, Lauren Pomerantz, BS, Christine Jarjies, MS, Natasha Galasso, BA, Rachel Neuman, Anita Kumar, MD, Oscar B Lahoud, MD, Connie Lee Batlevi, MDPhD, Paul A. Hamlin, MD, David J. Straus, MD, Ildefonso Rodriguez-Rivera, MD, Colette Owens, MD, Philip Caron, MD PhD, Andrew M. Intlekofer, MD PhD, Audrey Hamilton, MD, Steven M. Horwitz, MD, Lorenzo Falchi, MD, Erel Joffe, MD MSc, Maria Lia Palomba, Ariela Noy, MD, Matthew J Matasar, MD, Georgios Pongas, MD, Santosha Vardhana, MD PhD, Gottfried R. von Keudell, MD PhD, Joachim Yahalom, MD, Andrew D Zelenetz, MD PhD, Craig H. Moskowitz, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-138434
Published: 2020
Journal Articles

High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma

Alison J. Moskowitz, MD, Gunjan L. Shah, MDMS, Heiko Schoder, MD, Helen Hancock, ANP, Theresa Davey, MMSc, PA-C, Christopher Joong, BS, Lauren Pomerantz, BS, Christine Jarjies, MS, Anita Kumar, MD, Oscar B Lahoud, MD, Connie Lee Batlevi, MD PhD, Paul A. Hamlin, MD, David J. Straus, MD, Ildefonso Rodriguez-Rivera, MD, Colette Owens, MD, Philip Caron, MD PhD, Donald Steven Colbourn, MD, Andrew M. Intlekofer, MD PhD, Audrey Hamilton, MD, Steven M. Horwitz, MD, Erel Joffe, MDMSc, M. Lia Palomba, MD, Ariela Noy, MD, Matthew J Matasar, MD, Santosha Vardhana, MD PhD, Gottfried R. von Keudell, MD PhD, Joachim Yahalom, MD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Craig H. Moskowitz
Journal: Blood
Blood (2019) 134 (Supplement_1): 2837.
https://doi.org/10.1182/blood-2019-127575
Published: 2019
Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Alison J. Moskowitz, MD, Paola Ghione, MD, Eric D Jacobsen, MD, Jia Ruan, MD PhD, Jonathan H. Schatz, MD, Sarah Noor, MD, Patricia Myskowski, Helen Hancock, ANP, Theresa Davey, MMSc, PA-C, Obadi Obadi, Carlissa Onwasigwe, MPH, Nivetha Ganesan, MPH, Lauren Pomerantz, BS, Christine Jarjies, MS, Priyadarshini Kumar, Allison Sigler, Mark B. Geyer, MD, Ariela Noy, MD, David J. Straus, MD, Travis Hollmann, MD, Ahmet Dogan, MD PhD, Natasha Galasso, Giorgio Inghirami, MD, David M. Weinstock, MD, Steven M. Horwitz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4019.
https://doi.org/10.1182/blood-2019-125017
Published: 2019
Journal Articles

Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas

Alison J. Moskowitz, MD, Eric Jacobsen, MD, Jia Ruan, MD PhD, Jonathan H. Schatz, MD, Obadi Obadi, Kristin Motylinski, Christine Jarjies, MS, Natasha Galasso, Helen Hancock, NP, Theresa Davey, MPAS, Patricia Myskowski, MD, Ahmet Dogan, MD PhD, Giorgio Inghirami, MD, David M Weinstock, MD, Steven M. Horwitz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2922.
https://doi.org/10.1182/blood-2018-99-112123
Published: 2018